Tumor Analyses Reveal Squamous Transformation and Off-Target Alterations As Early Resistance Mechanisms to First-line Osimertinib in <i>EGFR</i> -Mutant Lung CancerAdam J. Schoenfeld, Helena A. Yu, Jason C. Chang et al.|Clinical Cancer Research|2020Cited by 381
COVID-19 in patients with lung cancerJie Luo, Matthew D. Hellmann, Hira Rizvi et al.|Annals of Oncology|2020Cited by 269
Acquired BRAF Rearrangements Induce Secondary Resistance to EGFR therapy in EGFR-Mutated Lung CancersMorana Vojnic, Marc Ladanyi, Daisuke Kubota et al.|Journal of Thoracic Oncology|2019Cited by 97